Dr. Atul Kumar, MD, PHD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 191
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Temple University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NM license MD2018-0133 -
Internal Medicine Physician
CA license A86359 (first issued 2004; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unm Hospital Albuquerque, NM
- Christus St Vincent Regional Medical Center Santa Fe, NM
- Yuma Regional Medical Center Yuma, AZ
- Lincoln County Medical Center Ruidoso, NM
- Los Alamos Medical Center Los Alamos, NM
Medical groups
- Presbyterian Healthcare Services (1,395 clinicians)
- Unm Medical Group Inc (1,047 clinicians)
- St Vincent Hospital (310 clinicians)
- Regional West Physicians Clinic (138 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 191
- Services billed
- 678
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 398 | 87 |
| Established patient office or other outpatient visit, 40-54 minutes | 108 | 37 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Albuquerque, NM | 30 |
| Prochlorperazine Maleate Other prescribers in Albuquerque, NM | 21 |
| Dexamethasone Other prescribers in Albuquerque, NM | 12 |
| Gabapentin Other prescribers in Albuquerque, NM | 12 |
| Prednisone Other prescribers in Albuquerque, NM | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $124 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $41.60 |
|---|---|
| Gilead Sciences, Inc. | $26.11 |
| Daiichi Sankyo Inc. | $24.74 |
| GlaxoSmithKline, LLC. | $16.04 |
| Novartis Pharmaceuticals Corporation | $15.75 |
| Food and Beverage | $124 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $45,418 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or…
Amgen Inc. - A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05785767 - A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Beone Medicines Ltd. · Completed · NCT03430843 - Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie Inc. · Active, not recruiting · NCT03539536
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.